Warhound 🚀 Raises $200M for Gene-Edited Military Dogs

What Warhound is building

Warhound wants to change how working dogs are sourced and prepared for demanding roles. The company says more than 80% of working dogs used by the US military come from Europe, and fewer than half of those dogs are fit for service. Warhound frames that as both a supply problem and an operational one: organizations need enough suitable dogs, and they need a way to identify and prepare them without burning years of effort on candidates that won't make it.

Military and law-enforcement dogs can handle tasks like bomb detection, searches, and other specialized work. In practice, it's not "dog versus robot." Machines can be better in some settings, and trained dogs can be better in others. The real questions are reliability and cost - what works consistently, and what it costs to run and maintain.

Warhound's proposal combines two main pieces:

• Biological selection and engineering: start with cell lines from high-performing working breeds, including Belgian Malinois and German Shepherds, then edit genes the company says could improve health or job-relevant traits.
• Cloning and breeding: use Colossal-owned cloning company Viagen to help produce dogs from selected cell lines.
• Training and equipment: train dogs for operational work, then add protective gear and technology intended to help handlers and improve situational awareness.

The company's stated goal is to develop dogs with characteristics suited to demanding missions. Lamm has talked about improving health and longevity, along with traits like speed, agility, and olfactory ability. That's the target - but it isn't the same thing as evidence that those traits can be changed reliably, passed on in a useful way, and shown to improve real field performance without introducing new problems.

Warhound's funding gives it runway, but it doesn't remove the tests that matter: producing healthy animals, getting predictable behavior, proving training works, enabling safe deployment, and building a sustainable way to supply customers.

Lamm told TechCrunch that he and Luckey started discussing the idea after meeting at a conference about a year earlier. Luckey raised the question of what more could be done for working dogs used by the US military. Lamm looked into supply and breeding challenges, and the concept grew from there.

There's a clear business logic to it. If organizations depend on a limited pool of dogs and many candidates never finish training, then increasing the number of healthy, suitable animals could matter. But the commercial case depends on more than creating an animal with selected traits. Buyers will also need confidence in training outcomes, health, how well handlers integrate with the dogs, ongoing support, and what happens to dogs that don't make it into service - or later need to retire.

How the biotech and equipment fit together

Warhound's biotech plan starts with cell lines from working breeds that already perform well in demanding roles. The company says these cell lines are stored in a biobank and will be edited to add desired characteristics or remove ones it associates with poor performance. Viagen is expected to support cloning and incubation, and Lamm says the first batch of dogs is expected to be born early next year.

This isn't the same as selective breeding over many generations - but it still doesn't make the hard parts go away. A gene edit needs a clear reason and a way to test whether it actually worked. The team has to show the edit produces the intended effect, that it shows up consistently, and that it doesn't come with unintended health or behavior issues. Traits like scent detection, agility, and temperament aren't interchangeable knobs. Real operational performance depends on the animal, its training, and the environment it's working in.

Cloning covers only part of the pipeline. It can reproduce an animal from a selected cell line, but it doesn't automatically produce a trained working dog. The dog still has to grow, stay healthy, respond to training, and work safely with a handler. Warhound hasn't yet demonstrated that combining genetic engineering and cloning will produce a higher share of service-ready dogs - one of the central claims the early program will have to test.

The second part of the plan comes from Anduril. The company is expected to provide hardware and software enhancements, including protective gear like vests and goggles. Lamm has described a possible bullet-resistant vest with sensors that could send information back to handlers about what's happening around the dog. Anduril's role is described as adding technology around the animal, rather than changing the animal from the inside.

That separation is helpful. A sensor-equipped vest is an engineering challenge: it has to fit properly, hold up in real operating conditions, communicate useful information, and avoid distracting or restricting the dog. And even if the sensors collect good data, that information has to reach a handler in a form they can use. Raw readings don't help unless they support decisions when they're needed.

So the equipment and the dog have to be evaluated together. A vest that works in a lab but interferes with movement isn't an improvement. A sensor that sends information a handler can't act on just adds complexity. And a dog that performs well without gear may behave differently once it's wearing protective equipment in a noisy, unfamiliar environment.

In short, Warhound isn't just selling "a genetically engineered dog." It's proposing a working capability that includes the animal, the handler, training, protective gear, sensors, and the procedures that tie them together. If any one piece fails, the whole system may underperform. Anduril's involvement could matter here - but integration will also become something Warhound has to measure, not just promise.

Colossal's broader biotech work - especially its de-extinction projects and efforts around gene cloning and reproducing animal genes - may give Warhound relevant experience. Still, past work doesn't automatically prove that this specific platform can meet the health, behavior, and operational standards required for working dogs. Each application needs its own evidence from its own testing and development.

What still needs to be proven

Warhound has announced a large funding round and a clear development direction. The next milestone is evidence. The company says the first dogs are expected to be born early next year and, ideally, enter service within two years. That timeline should be treated as a target, not a deployment date. A birth is only an early step in a long process that includes health monitoring, training, and evaluation for suitability.

Several questions will determine whether the program becomes useful in the field:

• Does the approach improve service readiness? The main metric isn't how many dogs are produced. It's how many become healthy, capable working dogs after training.
• Are health outcomes better over time? Warhound has discussed reducing risks like poor eyesight, cancer, hip dysplasia, and muscle atrophy. It will need to show how it measures those risks and whether outcomes improve as dogs mature.
• Are the traits reliable in real settings? A genetic target has to translate into repeatable performance across different training and operational environments - not just a promising result in controlled conditions.
• Does the equipment actually help handlers? Sensors, protective gear, and software should improve safety or decision-making without adding too much weight, distraction, or extra maintenance work.
• Can the program scale responsibly? Customers will need clear policies for training, ownership, animal welfare, ongoing care, and how Warhound handles dogs that don't complete service training.

Safety and oversight will also matter. On civilian safety, Lamm said the dogs would be trained like other military working dogs and managed by organizations that buy them. That describes the intended model, but responsibility in practice depends on more than training. Buyers, handlers, and Warhound need clear expectations around use, supervision, and care. Warhound says it's working with the American Humane Society to help certify its training program.

Warhound also says retired dogs may enter the Society's Military Working Dog Reunification Program, which helps find homes for retired military dogs, or another Society program. Retirement planning isn't a side detail. A responsible lifecycle has to cover what happens when dogs complete service, get injured, or don't qualify for deployment. Buyers and the public will care about how those arrangements actually work.

Government involvement is another open issue. Lamm says Warhound has briefed government groups about the business, but the source reporting doesn't describe a specific approval pathway. A briefing isn't the same thing as procurement, formal qualification, or authorization for use in a particular environment. The Department of Defense, police forces, and first responders may each have different requirements and buying processes.

Price is still undecided as well. That's understandable at this point, but it limits how buyers can compare Warhound's system with existing ways of acquiring working dogs. The comparison will need to go beyond the upfront cost. Training, equipment, handler time, veterinary care, and support over the dog's working life all contribute to total cost.

There's also a trade-off in what Warhound is trying to do. Genetic engineering could help target specific health or performance problems, and cloning could help reproduce selected genetics. In return, Warhound takes on technical, ethical, and operational scrutiny that a conventional breeding program doesn't face in the same way. The argument for the added complexity will be strongest if Warhound can show measurable gains - better health, higher training completion rates - without harming animal welfare.

Right now, the sensible way to evaluate the company is to separate what's known from what's projected. Funding, investors, the intended technology stack, and stated development goals are all on the record. The first dogs haven't entered service, Warhound hasn't shared pricing, and the impact of its genetic edits remains unproven. That's not a pro or anti claim. It's the baseline you'd want before treating a young program like a replacement.